Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma

Condition:   PD-1 Refractory Advanced Melanoma Interventions:   Biological: Responder-Derived Fecal microbiota transplantation (R-FMT;   Drug: Pembrolizumab;   Drug: Lenvatinib Sponsors:   Diwakar Davar;   Merck Sharp & Dohme LLC;   Gateway for Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials